Article

Regulatory SH3-SH2 domain mutations in BCR–ABL1 drive imatinib resistance and confer dasatinib sensitivity in chronic myeloid leukemia

2026-06-19

Abstract excerpt

<title>Abstract</title> <p> Selection of second-line tyrosine kinase inhibitor (TKI) in chronic myeloid leukemia (CML) is largely guided by kinase domain (KD) mutations in BCR::ABL1; however, a substantial subset of imatinib-resistant cases (~ 40%) lack targetable KD alterations, limiting therapeutic stratification. Given the critical role of the Src homology 2 (SH2) and SH3 domains in regulating BCR::ABL1 activ...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: da02371e-0cc1-58db-aa47-2fd5dbd4e688
DOI: 10.21203/rs.3.rs-9989394/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Regulatory SH3-SH2 domain mutations in BCR–ABL1 drive imatinib resistance and confer dasatinib sensitivity in chronic myeloid leukemiaDOI 10.21203/rs.3.rs-9989394/v1Read

ABL1-Directed Inhibitors for CML: Efficacy, Resistance and Future Perspectives.Semantic proximity Read

Mutation Profiling of BCR-ABL Kinase Domain in Chronic Myeloid Leukaemia Patients with Imatinib ResistanceSemantic proximity Read

BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinib.Semantic proximity Read

MUTATIONAL STATUS AND TREATMENT EFFICACY IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA.Semantic proximity Read

Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia.Semantic proximity Read

Mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and recent therapeutic strategies to overcome resistanceSemantic proximity Read

In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants.Semantic proximity Read

Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations.Semantic proximity Read

Overriding imatinib resistance with a novel ABL kinase inhibitor.Semantic proximity Read

Deep sequencing reveals the spectrum of BCR-ABL1 mutations upon front-line therapy resistance in chronic myeloid leukemia: An Eastern-Indian cohort study.Semantic proximity Read

Mutation in Abl kinase with altered drug binding kinetics indicates a novel mechanism of imatinib resistanceSemantic proximity Read

Targeting FLT3-TAZ signaling to suppress drug resistance in blast phase chronic myeloid leukemiaSemantic proximity Read